Mexameter erythema readings are a good representation of skin oxygenated hemoglobin, but not deoxygenated hemoglobin.
An international consensus establishes methotrexate dosing recommendations for psoriasis treatment and identifies current knowledge gaps on the topic.
Researchers evaluated the association between pharyngeal infections and incident psoriatic arthritis and psoriasis.
The long-term persistence of various biologic agents in treating psoriasis and psoriatic arthritis are investigated.
The efficacy of brodalumab by self-identified gender in patients with nail or scalp psoriasis is investigated.
Is short-term exposure to air pollutants associated with psoriasis flares?
Improvement in psoriasis clearance and its effect on pediatric patients’ quality of life is reviewed.
January 2022 FDA drug approvals include treatments for asthma, psoriatic arthritis, insomnia, and atopic dermatitis.
Potential risk factors associated with cognitive impairment in patients with psoriasis are assessed.
August and September 2021 FDA drug approvals include treatments for tick-borne encephalitis, idiopathic hypersomnia, schizophrenia, and atopic dermatitis.
Secukinumab vs adalimumab for treatment in patients with concomitant plaque psoriasis and active psoriatic arthritis during 52 weeks is reported.
Individuals with psoriasis/PsA have decreased ability to participate in social roles and activities, more depression symptoms.
At AAD VMX 2021, researchers presented data on skin clearance rates through 5 years with guselkumab in patients with moderate to severe plaque psoriasis.
In moderate-to-severe plaque psoriasis, bimekizumab is noninferior and superior to secukinumab and adalimumab, according to data from 2 studies.
Researchers sought to determine if a higher cumulative pain intensity is associated with premature mortality risk in patients with PsA.
Apremilast used for the treatment of psoriasis or psoriatic arthritis is not associated with a high risk of incident treated depression, anxiety, or anxiety plus depression.
Real-world data from patients with plaque psoriasis treated with guselkumab, who had previously been administered biologic agents is presented.
A novel study evaluated the effect of cardiometabolic syndrome on early vascular disease in patients with psoriasis.
The correlation between physician-evaluated PASI and BSA involvement and patient-evaluated DLQI and PDI was evaluated in measuring psoriasis disease severity.
Researchers assessed the effects of weight loss on disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity.